Back to top

Analyst Blog

athenahealth Inc. (ATHN - Analyst Report) posted adjusted loss of $3.0 million or 8 cents per share in the first quarter of 2014 in stark contrast to earnings of $6.0 million or 16 cents per share in the same quarter of 2013. The loss per share was broader than the Zacks Consensus Estimate of a loss of a penny for the quarter.

Reported loss was $8.1 million, or 21 cents per share compared with earnings of $0.7 million, or 2 cents per share, in the first quarter of 2013.

Revenues in the quarter rose 29.8% to $163.0 million but lagged the Zacks Consensus Estimate of $170 million. Excluding the Epocrates and other revenues (consisting of third-party tenant revenues) totaling $14.8 million, core athenahealth revenues rose 23% to $148.2 million in the quarter.

On a segment-wise basis, revenues from Business Services rose 26.8% year over year to $154.5 million while Implementation and Other revenues more than doubled to $8.5 million from $4.1 million in the first quarter of 2013.

Adjusted gross profits escalated 27.9% to $94.8 million but adjusted gross margin fell 80 basis points to 58.2% from 59.0% in the 2012-quarter. Adjusted operating loss was $3.6 million or 2.2% of sales in the quarter versus $4.3 million or 3.4% of sales in the prior-year quarter.

Financial Position

athenahealth had cash and cash equivalents of $51.3 million as of Mar 31, 2014, significantly down from $65.0 million as of Dec 31, 2013. Long-term debt stood at $185.0 million as of Mar 31, 2014 compared with $188.75 million as of Dec 31, 2013.

In the quarter, cash flow from operating activities was $14.1 million compared with an outflow of $5.5 million in the first quarter of 2013. Capital expenditure dipped 51.6% to $5.3 million from $11.0 million in 2013-quarter.

Zacks Rank

Currently, athenahealth carries a Zacks Rank #3 (Hold). The Zacks Consensus Estimates for 2014 revenues and earnings per share stand at $752 million and 33 cents.

Some better-ranked stocks in the medical products industry at this moment include Enzymotec Ltd. (ENZY - Snapshot Report), Edwards Lifesciences Corp. (EW - Analyst Report), and St. Jude Medical Inc. (STJ - Analyst Report). Enzymotec sports a Zacks Rank #1 (Strong Buy), while both Edwards Lifesciences Corp. and St. Jude Medical retain a Zacks Rank #2 (Buy).

Read the Full Research Report on ATHN
Read the Full Research Report on ENZY
Read the Full Research Report on STJ
Read the Full Research Report on EW


Zacks Investment Research

Please login to Zacks.com or register to post a comment.